498 related articles for article (PubMed ID: 11571447)
1. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
[TBL] [Abstract][Full Text] [Related]
2. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
Bumgardner GL; Ramos E; Lin A; Vincenti F;
Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
4. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
Nashan B; Light S; Hardie IR; Lin A; Johnson JR
Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
Wiseman LR; Faulds D
Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
[TBL] [Abstract][Full Text] [Related]
6. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
8. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
Ekberg H; Persson NH; Källen R; Gül-Baykurt N
Scand J Immunol; 2003 Dec; 58(6):670-7. PubMed ID: 14636424
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
12. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
Vincenti F; Nashan B; Light S
Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
[No Abstract] [Full Text] [Related]
14. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients.
Cole E; Landsberg D; Russell D; Zaltzman J; Kiberd B; Caravaggio C; Vasquez AR; Halloran P
Transplantation; 2001 Sep; 72(5):845-50. PubMed ID: 11571448
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab to prevent rejection after cardiac transplantation.
Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
[TBL] [Abstract][Full Text] [Related]
16. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
17. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
18. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
Kahan BD; Rajagopalan PR; Hall M
Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
Vincenti F
Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
